Matches in SemOpenAlex for { <https://semopenalex.org/work/W1970483080> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W1970483080 endingPage "A76" @default.
- W1970483080 startingPage "A76" @default.
- W1970483080 abstract "Worldwide prevalence of overactive bladder (OAB) is close to 10% in adults. The urgent feeling to go to the toilet, frequency of voids and urinary incontinence affects lifestyle and productivity of patients. The aim of this study was to estimate the cost-effectiveness of tolterodine in the managing of OAB from an institutional perspective. A four-state Markov model was performed to estimate health and economic consequences during a time horizon of one year (one-month cycles). Effectiveness measures were mean percentage reduction in: number of voids per day, number of urinary urgency events per day and number of urinary incontinence events per day. Transition probabilities were obtained from a meta-analysis employing international published literature. Comparators were tolterodine (2 mg bid) and tablets of oxybutynin (5 mg tid) as reference treatment. Resource use was obtained from the Instituto Mexicano del Seguro Social (IMSS) databases (n=377 cases). Costs were extracted from institutional (IMSS) official sources. Costs included: visits to general practitioners and urologists, hospitalization, drugs, medical procedures, laboratory tests, imagenology and adverse events management. Probabilistic sensitivity analyses were performed employing bootstrapping techniques. Acceptability curves were constructed. Tolterodine and oxybutynin annual costs per patient were: US$1,654.55 [95%CI US$1,486.97-US$1,822.13] and US$1,537.38 [95%CI US$1,389.42-US$1,685.33], respectively (p>0.05). Tolterodine exhibits better outcomes than reference in all effectiveness measures considered (p<0.05). Incremental cost-effectiveness ratios for additional percentage reduction of: number of voids, events of urinary urgency and events of urinary incontinence were: US$1,307.34 [95%CI US$1,268.73-US$1,345.96]; US$1,091.39 [95%CI US$1,059.15-US$1,123.62] and US$ 2,915.31 [95%CI US$2,829.14-US$3,001.42], respectively. Acceptability curve showed that the probability of tolterodine being cost-effective is close to one at a willingness to pay of US$3,170 (regarding percent reduction of number of voids). Tolterodine is more effective than oxybutynin with similar treatment costs representing a more efficient alternative in the management of OAB at the IMSS." @default.
- W1970483080 created "2016-06-24" @default.
- W1970483080 creator A5010107427 @default.
- W1970483080 creator A5012027205 @default.
- W1970483080 creator A5022627722 @default.
- W1970483080 creator A5023367156 @default.
- W1970483080 creator A5057426873 @default.
- W1970483080 creator A5065160022 @default.
- W1970483080 creator A5084636197 @default.
- W1970483080 date "2011-05-01" @default.
- W1970483080 modified "2023-09-27" @default.
- W1970483080 title "PUK12 COST-EFFECTIVENESS OF TOLTERODINE AS TREATMENT FOR OVERACTIVE BLADDER (OAB) IN ADULT MEXICAN PATIENTS" @default.
- W1970483080 doi "https://doi.org/10.1016/j.jval.2011.02.427" @default.
- W1970483080 hasPublicationYear "2011" @default.
- W1970483080 type Work @default.
- W1970483080 sameAs 1970483080 @default.
- W1970483080 citedByCount "0" @default.
- W1970483080 crossrefType "journal-article" @default.
- W1970483080 hasAuthorship W1970483080A5010107427 @default.
- W1970483080 hasAuthorship W1970483080A5012027205 @default.
- W1970483080 hasAuthorship W1970483080A5022627722 @default.
- W1970483080 hasAuthorship W1970483080A5023367156 @default.
- W1970483080 hasAuthorship W1970483080A5057426873 @default.
- W1970483080 hasAuthorship W1970483080A5065160022 @default.
- W1970483080 hasAuthorship W1970483080A5084636197 @default.
- W1970483080 hasBestOaLocation W19704830801 @default.
- W1970483080 hasConcept C112930515 @default.
- W1970483080 hasConcept C126322002 @default.
- W1970483080 hasConcept C126894567 @default.
- W1970483080 hasConcept C142724271 @default.
- W1970483080 hasConcept C197934379 @default.
- W1970483080 hasConcept C204787440 @default.
- W1970483080 hasConcept C2777844464 @default.
- W1970483080 hasConcept C2778531004 @default.
- W1970483080 hasConcept C2778941218 @default.
- W1970483080 hasConcept C2781020410 @default.
- W1970483080 hasConcept C3019080777 @default.
- W1970483080 hasConcept C71924100 @default.
- W1970483080 hasConceptScore W1970483080C112930515 @default.
- W1970483080 hasConceptScore W1970483080C126322002 @default.
- W1970483080 hasConceptScore W1970483080C126894567 @default.
- W1970483080 hasConceptScore W1970483080C142724271 @default.
- W1970483080 hasConceptScore W1970483080C197934379 @default.
- W1970483080 hasConceptScore W1970483080C204787440 @default.
- W1970483080 hasConceptScore W1970483080C2777844464 @default.
- W1970483080 hasConceptScore W1970483080C2778531004 @default.
- W1970483080 hasConceptScore W1970483080C2778941218 @default.
- W1970483080 hasConceptScore W1970483080C2781020410 @default.
- W1970483080 hasConceptScore W1970483080C3019080777 @default.
- W1970483080 hasConceptScore W1970483080C71924100 @default.
- W1970483080 hasIssue "3" @default.
- W1970483080 hasLocation W19704830801 @default.
- W1970483080 hasOpenAccess W1970483080 @default.
- W1970483080 hasPrimaryLocation W19704830801 @default.
- W1970483080 hasRelatedWork W1572722564 @default.
- W1970483080 hasRelatedWork W1979349027 @default.
- W1970483080 hasRelatedWork W2016182265 @default.
- W1970483080 hasRelatedWork W2024445028 @default.
- W1970483080 hasRelatedWork W2297239795 @default.
- W1970483080 hasRelatedWork W2409587761 @default.
- W1970483080 hasRelatedWork W2413196837 @default.
- W1970483080 hasRelatedWork W2553564466 @default.
- W1970483080 hasRelatedWork W3011923719 @default.
- W1970483080 hasRelatedWork W4239548330 @default.
- W1970483080 hasVolume "14" @default.
- W1970483080 isParatext "false" @default.
- W1970483080 isRetracted "false" @default.
- W1970483080 magId "1970483080" @default.
- W1970483080 workType "article" @default.